Pemetrexed (Pemetrexed) Patent Expiration, LOE Window & CMS Spending

Pemetrexed (Pemetrexed) by Teva Pharmaceuticals: FDA Orange Book LOE 2035-03-26, 2 AB generics, $159K 2024 CMS Part D & Medicaid spend, and $3,995 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN208419 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-03-26
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$159K
2024 Medicare Part D Spend$29K
2024 Medicaid Spend$130K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,995 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.